Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients - Analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Sharma, Rohini ^a   Cunningham, David ^b   Smith, Paul ^c   Robertson, Graham ^d   Dent, Owen ^d   Clarke, Stephen J ^d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; PMITCEBO PROTOCOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

AGE; ANEMIA; ARTICLE; B CELL LYMPHOMA; B SYMPTOM; BLOOD TOXICITY; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG USE; HUMAN; INFLAMMATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHYSICAL PERFORMANCE; PROGNOSIS; RASH; SYMPTOM; THROMBOCYTOPENIA; AGED; COHORT ANALYSIS; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; LEUKOPENIA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MITOXANTRONE; PREDNISOLONE; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 67449115697     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-153     Document Type: Article

References (25)

1. Chen-Hardee S Chrischilles EA Voelker MD Brooks JM Scott S Link BK Delgado D Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States) Cancer Causes Control 2006, 17:647-54. 10.1007/ s10552-005-0502-4 16633911
2. Du XL Osborne C Goodwin JS Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer J Clin Oncol 2002, 20:4636-42. 2566741 12488407 10.1200/ JCO.2002.05.088
3. Hassett MJ O'Malley AJ Pakes JR Newhouse JP Earle CC Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer J Natl Cancer Inst 2006, 98:1108-17. 16912263
4. Jemal A Siegel R Ward E Murray T Xu J Thun MJ Cancer statistics, 2007 CA Cancer J Clin 2007, 57:43-66. 10.3322/canjclin.57.1.43 17237035
5. Kwak LW Halpern J Olshen RA Horning SJ Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis J Clin Oncol 1990, 8:963-77. 2348230
6. Legouffe E Rodriguez C Picot MC Richard B Klein B Rossi JF Commes T C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma Leuk Lymphoma 1998, 31:351-7. 9869199
7. Seymour JF Talpaz M Cabanillas F Wetzler M Kurzrock R Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma J Clin Oncol 1995, 13:575-82. 7884418
8. Preti HA Cabanillas F Talpaz M Tucker SL Seymour JF Kurzrock R Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma Ann Intern Med 1997, 127:186-94. 9245223
9. Niitsu N Okamato M Nakamine H Yoshino T Tamaru J Nakamura S Higashihara M Hirano M Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma Eur J Haematol 2002, 68:91-100. 10.1034/j.1600-0609.2002.01609.x 12038454
10. Pedersen LM Klausen TW Davidsen UH Johnsen HE Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma Ann Hematol 2005, 84:510-6. 10.1007/s00277-005-1020-x 15834569
11. Mahmoud FA Rivera NI The role of C-reactive protein as a prognostic indicator in advanced cancer Curr Oncol Rep 2002, 4:250-5. 10.1007/ s11912-002-0023-1 11937016
12. Renton KW Regulation of drug metabolism and disposition during inflammation and infection Expert Opin Drug Metab Toxicol 2005, 1:629-40. 10.1517/17425255.1.4.629 16863429
13. Aitken AE Richardson TA Morgan ET Regulation of drug-metabolizing enzymes and transporters in inflammation Annu Rev Pharmacol Toxicol 2006, 46:123-49. 10.1146/annurev.pharmtox.46.120604.141059 16402901
14. Rivory LP Slaviero KA Clarke SJ Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response Br J Cancer 2002, 87:277-80. 10.1038/sj.bjc.6600448 12177794
15. Slaviero KA Clarke SJ Rivory LP Inflammatory response: An unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy Lancet Oncol 2003, 4:224-32. 10.1016/ S1470-2045(03)01034-9 12681266
16. Burton C Linch D Hoskin P Milligan D Dyer MJ Hancock B Mouncey P Smith P Qian W MacLennan K Jack A Webb A Cunningham D A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma Br J Cancer 2006, 94:806-13. 10.1038/sj.bjc.6602975 16508640
17. Trikha M Corringham R Klein B Rossi JF Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence Clin Cancer Res 2003, 9:4653-65. 14581334
18. Mayo PR Skeith K Russell AS Jamali F Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis Br J Clin Pharmacol 2000, 50:605-13. 2015009 11136300 10.1046/ j.1365-2125.2000.00314.x
19. Chang KC Bell TD Lauer BA Chai H Altered theophylline pharmacokinetics during acute respiratory viral illness Lancet 1978, 1:1132-3. 10.1016/ S0140-6736(78)90305-7 77421
20. Kraemer MJ Furukawa CT Koup JR Shapiro GG Pierson WE Bierman CW Altered theophylline clearance during an influenza B outbreak Pediatrics 1982, 69:476-80. 7070895
21. Richardson TA Morgan ET Hepatic cytochrome P450 gene regulation during endotoxin-induced inflammation in nuclear receptor knockout mice J Pharmacol Exp Ther 2005, 314:703-9. 10.1124/jpet.105.085456 15860574
22. Abdel-Razzak Z Loyer P Fautrel A Gautier JC Corcos L Turlin B Beaune P Guillouzo A Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture Mol Pharmacol 1993, 44:707-15. 8232220
23. Morgan ET Regulation of cytochromes P450 during inflammation and infection Drug Metab Rev 1997, 29:1129-88. 10.3109/03602539709002246 9421688
24. Sunman JA Hawke RL LeCluyse EL Kashuba AD Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes Drug Metab Dispos 2004, 32:359-63. 10.1124/dmd.32.3.359 14977871
25. Charles KA Rivory LP Brown SL Liddle C Clarke SJ Robertson GR Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer Clin Cancer Res 2006, 12:7492-7. 10.1158/ 1078-0432.CCR-06-0023 17189422